Landos Biopharma to Participate in Upcoming Digestive Disease Week Conference and BIO International Convention

• At Digestive Disease Week, Andrew Leber, PhD, Scientific Director at Landos Biopharma, will present findings on the mechanisms of action for its lead candidate in a poster (Abstract: Tu1739) titled Translation of Immunometabolic Mechanisms of BT-11 to Humans with Crohn’s Disease on June 5^th from 12:00 – 2:00 pm.
• At Digestive Disease Week, Landos will also convene a meeting of its Clinical Advisory Board (CAB) to discuss its Phase 2 clinical program in Crohn’s disease and ulcerative colitis on June 3^rd . Landos’ CAB is composed of key opinion leaders in Crohn’s and colitis: Drs. William Sandborn, Jean-Frederic Colombel, Fabio Cominelli, Francisco Sylvester and Maria Abreu.
• At the BIO International Convention in Boston, MA, Dr. Josep Bassaganya-Riera, Chairman and CEO, will participate on the “Translating Immunological Insights from Oncology to Other Disease Areas” panel on June 5^th from 1:45 – 2:45 pm.
• Also, at the BIO International Convention, Dr. Bassaganya-Riera will present a corporate and clinical program update on June 5^th from 4:15 pm – 4:30 pm.

“We are pleased to have the opportunity to present our company and science at these two prestigious conferences at a time when BT-11 is entering the clinical development stage,” said Dr. Bassaganya-Riera. “Our lead compound BT-11 is a first-in-class oral therapeutic for Crohn’s disease and ulcerative colitis that has the potential to disrupt the treatment paradigm. We expect to file two INDs and initiate a Phase 1 clinical trial in the coming months.”

About BT-11

Landos’ lead product candidate BT-11 is a first-in-class, orally active therapeutic that acts locally in the gastrointestinal tract for treatment of Crohn’s disease and ulcerative colitis. BT-11 has shown outstanding therapeutic efficacy in preclinical models, a benign safety profile without the concerns of systemic exposure, and it is advancing toward two Investigational New Drug (IND) filings in 2018. BT-11 intercepts IBD by decreasing the production of inflammatory mediators and increasing anti-inflammatory molecules within the gastrointestinal tract.

About Landos Biopharma, Inc.

Landos Biopharma, Inc. is an emerging biopharmaceutical company focused on the discovery and development of first-in-class oral therapeutics for patients with autoimmune diseases. Landos’ lead clinical asset, BT-11, is a novel, oral, locally-acting small molecule targeting the Lanthionine Synthetase C-Like 2 (LANCL2) pathway in the gastrointestinal tract for treatment of inflammatory bowel disease (IBD) and is expected to enter clinical testing for Crohn’s disease and ulcerative colitis in 2018. Landos also has a robust pipeline of compounds for other autoimmune diseases. Landos is headquartered in Blacksburg, VA. For more information, please visit www.landosbiopharma.com or contact info@landosbiopharma.com or follow us @Landosbio.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180523005171/en/